Current practice of Latin American centers in the treatment of peritoneal diseases with cytoreductive surgery with HIPEC

Imagem de Miniatura
Arquivos
art_QUADROS_Current_practice_of_Latin_American_centers_in_the_2018.PDF (274.29 KB)
Citações na Scopus
13
Tipo de produção
article
Data de publicação
2018
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCI LTD
Autores
QUADROS, C. A.
LAPORTE, G. A.
HUGUENIN, J. F. L.
BARRETO, E. J. S. S.
V, A. Barros
OLIVEIRA, A. F.
CARVALHO, A. L. L.
PETRUZZIELLO, A.
PAULA, A. C.
URBANO-RUIZ, A.
Citação
EJSO, v.44, n.11, p.1800-1804, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Introduction: A combination therapy of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has been proposed as a treatment option in patients with peritoneal metastasis of colorectal, ovarian, gastric cancers and sarcomas and as a current standard treatment for pseudomyxoma peritonei and peritoneal mesothelioma. There is a need to standardize its indication, drugs selection along with their concentrations and ways to deliver peritoneal chemotherapy solutions for best outcomes. Aim of the study: To investigate the current practice of Latin American (LA) Centers in which peritoneal diseases (PD) are treated. Patient and Methods: All centers from Latin American Registry of Peritoneal Diseases (LARPD) were invited to participate in a two rounds online survey, to describe their current practice in all indications of CRS with HIPEC for PD. Results: 76 out of 84 LARPD's centers answered the survey, with a response rate of 90,5%. The results represent the current practice of 248 surgeons that are members of LARPD's centers, in 8 LA countries, that at the time of the study had treated 2682 patients with CRS with HIPEC. All current practice aspects including indications, contra-indications, patient selection, methods of peritoneal chemotherapy delivery and treatment protocols are described in this manuscript. Conclusions: This survey is the first LA effort to publish current practice indications and treatment protocols of PD. Achieving consensus of best therapeutic options is essential to provide the best possible outcomes for patients with PD who could benefit from CRS with HIPEC therefore aiming at standardization of the procedure.
Palavras-chave
Cytoreductive surgery, HIPEC, Peritoneal carcinomatosis, Intraperitoneal chemotherapy, Peritoneal metastasis, Peritoneal disease
URI
https://observatorio.fm.usp.br/handle/OPI/30777
Referências
  1. Baratti D, 2008, J SURG ONCOL, V98, P258, DOI 10.1002/jso.21056
  2. Carr NJ, 2016, AM J SURG PATHOL, V40, P14, DOI 10.1097/PAS.0000000000000535
  3. Chua TC, 2013, J SURG ONCOL, V107, P566, DOI 10.1002/jso.23189
  4. Chua TC, 2012, J CLIN ONCOL, V30, P2449, DOI 10.1200/JCO.2011.39.7166
  5. Chua TC, 2009, J SURG ONCOL, V99, P109, DOI 10.1002/jso.21177
  6. Di Giorgio A, 2008, CANCER, V113, P315, DOI 10.1002/cncr.23553
  7. Elias D, 2010, J CLIN ONCOL, V28, P63, DOI 10.1200/JCO.2009.23.9285
  8. Elias D, 2009, J CLIN ONCOL, V27, P681, DOI 10.1200/JCO.2008.19.7160
  9. Franko J, 2012, J CLIN ONCOL, V30, P263, DOI 10.1200/JCO.2011.37.1039
  10. Glehen O, 2010, ANN SURG ONCOL, V17, P2370, DOI 10.1245/s10434-010-1039-7
  11. Goere D, 2013, ANN SURG, V257, P1065, DOI 10.1097/SLA.0b013e31827e9289
  12. GOUGH DB, 1994, ANN SURG, V219, P112, DOI 10.1097/00000658-199402000-00002
  13. Helm JH, 2015, ANN SURG ONCOL, V22, P1686, DOI 10.1245/s10434-014-3978-x
  14. Jacquet P, 1996, Cancer Treat Res, V82, P359
  15. Kusamura S, 2008, J SURG ONCOL, V98, P247, DOI 10.1002/jso.21051
  16. Kusamura S, 2008, J SURG ONCOL, V98, P232, DOI 10.1002/jso.21058
  17. Mohamed F, 2009, CANCER J, V15, P196, DOI 10.1097/PPO.0b013e3181a58d56
  18. Rajan F, 2009, MANAGEMENT PERITONEA, P3
  19. RONNETT BM, 1995, AM J SURG PATHOL, V19, P1390, DOI 10.1097/00000478-199512000-00006
  20. Smeenk RM, 2007, BRIT J SURG, V94, P1408, DOI 10.1002/bjs.5863
  21. Spiliotis J, 2015, ANN SURG ONCOL, V22, P1570, DOI 10.1245/s10434-014-4157-9
  22. Sugarbaker P, 2016, ANN SURG ONCOL, V23, P1501, DOI 10.1245/s10434-015-4960-y
  23. Sugarbaker PH, 2006, LANCET ONCOL, V7, P69, DOI 10.1016/S1470-2045(05)70539-8
  24. SUGARBAKER PH, 1995, ANN SURG, V221, P29, DOI 10.1097/00000658-199501000-00004
  25. van Driel WJ, 2018, NEW ENGL J MED, V378, P230, DOI 10.1056/NEJMoa1708618
  26. Verwaal VJ, 2003, J CLIN ONCOL, V21, P3737, DOI 10.1200/JCO.2003.04.187
  27. Yan TD, 2009, J CLIN ONCOL, V27, P6237, DOI 10.1200/JCO.2009.23.9640
  28. Zivanovic O, 2015, INT J CANCER, V136, P699, DOI 10.1002/ijc.29011

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InRad
Artigos e Materiais de Revistas Científicas - LIM/62
Artigos e Materiais de Revistas Científicas - ODS/03